The role of ligand-receptor (LR) pairs in disease progression has been explored in bladder cancer. However, the relationship of LR pairs with cancer prognosis and treatment response remains poorly understood.
We characterized the LR pair network and identified three distinct molecular subtypes with distinct biologic features based on the TCGA database (n = 406) and validated in GSE13507 (n = 165) and GSE32894 (n = 224). Three subtypes were compared for differences in patient clinical characteristics, genomic, and transcriptomic features. A multivariate Lasso Cox regression model was applied to construct an LR pairs-based scoring model to stratify the prognostic risk of patients. We demonstrated the high LR. score patients had better responses in chemotherapy, while low LR. score patients may benefit from immune checkpoint blockade (ICB). Collectively, we identified three LR pair-related subtypes associated with prognosis. We constructed and validated a LR pairs-based gene signature, which helps to predict prognosis and differentiate the susceptible population to chemotherapy and immunotherapy in patients with bladder cancer. Among the LR pairs significantly related to prognosis, ANAX1-EGFR axis was found to be potential therapeutic target for treatment of bladder cancer.
Frontiers in cell and developmental biology. 2022 Jun 17*** epublish ***
Chuang Wang, Honglei Wan, Han Zhang, Bo Yang, Wen-Kuan Huang, Wenguo Sun
Department of Urology, Guilin People's Hospital, Guilin, China., Department of Urology, Handan First Hospital, Handan, China., Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan., Department of Urology, The Affiliated Hospital of Guilin Medical University, Guilin, China.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/35784457